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Abstract: Down syndrome (DS) is one of the most common birth defects in the United States, the most common genomic disorder of
intellectual disability, and results from trisomy 21. This chromosome disorder causes an extensive, heterogenous phenotype that results
in a broad presentation of symptoms that includes atlantoaxial instability, congenital heart defects, muscle hypotonia, hypothyroidism,
hematologic disorders, recurrent infections, and autoimmune diseases. The autoimmune diseases are caused by immune system
dysregulation that results in increased pro-inflammatory cytokines, along with other innate and adaptive immune system dysregulation.
This is the likely cause of the increased risk of inflammatory arthritis or Down syndrome-associated arthritis (DA) seen in individuals
with DS. Most individuals with DA present with polyarticular (five or more joints with arthritis at presentation of disease), rheumatoid
factor and anti-nuclear antibody negative disease that is aggressive with bone and joint damage at presentation. There is notable delay
in diagnosis of DA as there are no formal guidelines on screening or monitoring for inflammatory arthritis in individuals with DS.
Once diagnosed, and despite aggressive therapy with disease modifying antirheumatic drugs, disease burden is high for those with DA.
Therapy can also be challenging for those with DA as many require second and third-line disease modifying therapies. Many also
struggle with medication toxicity and ineffectiveness that further causes challenges with management and outcomes. The purpose of
this current review is to provide an up-to-date summary of the literature related to DA in children and adolescents with focus on
presentation, diagnosis, and management considerations, along with current barriers that inhibit optimal care.
Keywords: Down syndrome, Down syndrome-associated arthritis, diagnosis, management, outcomes

Introduction
Down syndrome (DS) is one of the most common birth defects in the United States with an estimated birth prevalence of
12.6 per 10,000 live births.1 DS is also the most common genomic disorder of intellectual disability and results from
a trisomy of human chromosome 21.2 This chromosomal disorder results from meiotic nondisjunction most commonly,
but may also result from translocation. Mosaicism and partial trisomy 21 can also occur, and these are usually associated
with fewer clinical features compared with nondisjunction and translocation.3 Trisomy 21 can present with extensive,
heterogenous phenotype that can affect many bodily systems and results from a dosage imbalance of genes located on
human chromosome 21.4 Due to the heterogenous phenotype, a broad presentation of symptoms may occur. Individuals
with DS commonly present with obstructive sleep apnea, congenital heart defects, intellectual disability, atlantoaxial
instability, muscle hypotonia (possibly caused by the reduced neuronal density and cerebellar hypoplasia), and short
stature. They are also at increased risk to develop anxiety disorders, epilepsy, hypothyroidism, hearing and vision
problems, hematologic disorders, and recurrent infections.2 Autoimmune diseases have also been reported at an increased
incidence,5,6 which poses a unique medical challenge for individuals with DS and their medical care providers.
Inflammatory arthritis in children with DS was first described in 1984 and was termed Down syndrome arthropathy,7
however, the term Down syndrome-associated arthritis (DA) has been proposed to better describe the inflammatory
nature of the disease.8 Since 1984, studies have shown that DA is under-recognized with a delay in diagnosis of up to
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three years between symptoms onset and diagnosis.9–11 Most individuals with DA present with polyarticular (five or
more joints with arthritis at presentation of disease), rheumatoid factor (RF) and anti-nuclear antibody (ANA) negative
disease.8–11 There are reports that DA is more prevalent than juvenile idiopathic arthritis (JIA),7,8,10,11 which is the most
common pediatric rheumatologic disease.12 DA appears more aggressive than JIA with more bone and joint damage at
presentation,9,11 and despite aggressive therapy with disease modifying antirheumatic drugs (DMARDs) and biologic
therapy, disease burden is higher for those with DA compared to those with JIA.10,13 Therapy can also be challenging for
those with DA as many require second-line disease modifying therapies,9,10 but also struggle with medication toxicity
and ineffectiveness.9,10,13
The purpose of this current review is to provide an up-to-date summary of the literature related to DA in children and
adolescents with focus on presentation, diagnosis, and management considerations, along with current barriers that
inhibit optimal care. Additionally, goals are outlined to optimize outcomes through earlier diagnosis and monitoring of
disease, with considerations for therapy management.

Prevalence and Clinical Features of DA
There are no population-based prevalence studies of DA within the United States, but previous reports suggest an
estimated prevalence of 8.7 to 12 per 1000 individuals with DS.7,11 In another study that used a novel screening tool to
evaluate for inflammatory arthritis in children with DS there was one individual that was diagnosed with arthritis out of
91 screened,14 which would equate to one percent of the population screened or 10 per 1000 individuals with DS. For
comparison, congenital heart disease occurs in 40% to 50% of individuals with DS, while thyroid disease is reported in
4% to 18%, Celiac disease in 5% and atlantoaxial instability in 1% to 2%.15 Additionally, in Ireland the estimated
prevalence of DA is 20 per 1000 individuals with DS,8 however, the Irish incidence for DS is the highest in Europe at 1
in 547 births.16 The current proposed definition of DA is inflammatory arthritis in an individual with DS. The definition
of inflammatory arthritis is adapted from JIA,17 and is defined as swelling within a joint, or limitation in the range-ofmotion of joint movement with or without pain or tenderness that persists for at least 6 weeks duration, is observed by
a physician and is not due to primary mechanical disorder or other identifiable cause outside of DS. The definition has
raised debate among the rheumatology community as the majority feel DA is the same disease as JIA,18 and because of
this, individuals with DA are commonly reported as part of JIA cohorts. This has provided a framework to compare
differences in disease presentation, course, outcomes, and therapy between individuals with DA and JIA. The diagnosis
of JIA is a clinical diagnosis based on the Edmonton 2001 International League of Associations for Rheumatology
(ILAR) criteria.17 The definition for JIA includes the subtypes: oligoarticular (four or less joints with arthritis at
diagnosis), polyarticular (five or more joints with arthritis at diagnosis and with either RF positive or negative), systemiconset (arthritis with fever of at least 2 weeks duration noted to be daily, with quotidian pattern for at least 3 days, and
accompanied by classic rash, lymphadenopathy, hepatosplenomegaly, or serositis), enthesitis-related arthritis (arthritis
and enthesitis or arthritis or enthesitis with two or more of the following: sacroiliac joint tenderness, inflammatory low
back symptoms, positive HLA-B27, family history of HLA-B27-associated disease, acute symptomatic anterior uveitis,
arthritis in male after six years of age), and psoriatic arthritis (arthritis plus psoriasis or signs of psoriasis such as
dactylitis, nail pitting, onycholysis or first degree relative with psoriasis).
Of the individuals with DA most present with a polyarticular course, with RF and ANA negative disease at
presentation (Tables 1 and 2).7–11,13,19–24 The second most common presentation is oligoarticular course, however, of
the studies that followed individuals with DA over time, almost 70% of those that presented with oligoarticular disease
progressed to polyarticular disease,9,11,21 which makes psoriatic arthritis more likely the second most common presentation of inflammatory arthritis reported in DS. This is different compared to JIA where most individuals present with
oligoarticular, ANA positive disease followed by polyarticular, RF negative disease.8,25 Additionally, most of those with
oligoarticular and polyarticular JIA tend to be female, whereas those with DA have less discrepancy in sex predilection.
The average age range at arthritis onset is also different between JIA and DA, with individuals with JIA presenting at an
earlier age. This correlates with the most common JIA subtype of oligoarticular disease, which is mostly seen in toddlers.
Polyarticular JIA has a biphasic trend with peaks between 1 and 3 years of age and 9 and 14 years of age.25 Reports of
DA suggest an older average age at presentation of arthritis between 6.9 and 7.4 years,9,13 however, another report
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suggests that most of those with DA present in the 13 to 20 year age range.8 Despite the difference between these two
studies of DA, both report differences compared to polyarticular JIA, and may represent a biphasic trend in DA that
occurs later than the biphasic trend seen in JIA. Many studies report morning stiffness as a symptom in individuals with
DA with most studies reporting greater than 50% of individuals endorsing morning stiffness, however, one study reported
38% of individuals with morning stiffness (Table 1).
Other differences exist between those with DA and JIA that include laboratory testing and imaging at disease
presentation (Table 2). Earlier reports (prior to 2003) suggest the majority (88% to 100%) of those with DA present with
elevated erythrocyte sedimentation rate (ESR),7,10,21 however, more recent reports (after 2009) suggest a lower percentage (17% to 56%) will have an elevated ESR at presentation.8,9,11,13 While the cause of this is not clear, it has been
proposed that the more recent reports of DA were diagnosed earlier in the course of disease compared to the earlier
reported cases,13 and when compared to JIA, significantly more individuals with DA had an elevation of ESR at
diagnosis.8 There were also significantly more individuals with JIA that had a positive ANA compared to those with
DA.8 Additionally, there are several reports of high positivity of anti-cyclic citrullinated peptide (CCP) antibody, RF, and
other autoantibodies found in individuals with DS, however, these laboratory findings have not been correlated with
presence of arthritis or rheumatic disease in those individuals.26–28 It is unclear what the significance of this is and likely
indicates immune dysregulation in those with DS. It should be noted that anti-CCP and RF are rarely positive or elevated
in those with DA. While many individuals with DA will present with abnormal laboratory tests at diagnosis, there is no
consistently abnormal laboratory test seen across studies. Of the cases of DA reported, 28% to 44% of individuals
presented with normal laboratory tests (normal ESR, CRP, and negative ANA, RF, CCP, and HLA-B27) at presentation
of disease.9,13 Another difference between individuals with DA and JIA is imaging at diagnosis. For individuals with DA,
imaging studies showed more joint abnormalities consistent with inflammatory disease such as osteopenia, bony
erosions, joint space narrowing, effusion, synovitis, and tenosynovitis. When imaging studies at diagnosis of arthritis
are compared between those with DA and JIA, the individuals with DA have significantly more joint damage
present.8,9,13
Another difference noted between those with DA and JIA is the incidence of uveitis (Table 2), which is more
prevalent in JIA, especially those with a positive ANA. There are only three patients reported in the literature with uveitis
and DA,9 with two having HLA-B27 positive enthesitis-related arthritis with acute anterior uveitis and one having
polyarticular RF, ANA, and HLA-B27 negative disease with chronic uveitis. While individuals with JIA are at increased
risk of anterior uveitis, especially those with oligoarticular disease and ANA positivity,29 individuals with DA do not
seem to have the same risk, even those with a positive ANA. For individuals with JIA, there is a known association
between acute anterior uveitis and HLA-B27,30 and about 14% of those with polyarticular RF negative JIA develop
chronic anterior uveitis.31 This may indicate that those with DA and HLA-B27 are at increased risk of acute uveitis,
however, the numbers are too low to draw firm conclusions. More information is needed to further evaluate the risk of
acute and chronic uveitis and determine if more frequent eye screening in patients with DA is necessary or if certain
features increase the risk for inflammatory eye disease in this population.

Etiology and Pathogenesis.
The etiology and pathogenesis of DA has not been fully described, but since the 1970s there has been emerging evidence
that individuals with DS have clear differences in their immune system compared to those without DS. This is supported
by the increased incidence of autoimmune diseases such as Celiac and Diabetes mellitus type I, leukemia, and infections,
especially pneumonia. Since that time work has been done that supports the idea that there is an intrinsic defect in the
immune system of those with DS.32 Evidence has grown and reports show a diminished expansion of T and
B lymphocytes, which strongly suggests a disturbance in the adaptive immune system in those with DS.33 Further,
when those with DS were compared to healthy, neurotypical controls it was shown that those with DS have significantly
higher percentages of interferon (IFN)-γ-producing CD4+ and CD8+ cells with higher Th1/Th2 ratio.34 There is also
evidence to show that pro-inflammatory cytokines are dysregulated in individuals with DS. A study that compared
healthy neurotypical children to healthy children with DS showed that those with DS had elevated IFN-γ, and tumor
necrosis factor (TNF)-α, and decreased levels of interleukin (IL)-10.35 A meta-analysis from 2017 was performed
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Table 1 Clinical Features of Down Syndrome-Associated Arthritis (at Diagnosis)
Case SeriesReference

117

218

36

49

519

610

720

821

98

107

1122

1212

Patients

1

1

6

9

4

9

1

11

43

33

1

36

155

Female sex

1

1

2

5

3

4

1

6

25

15

1

24

88 (57%)

Celiac disease

NR

NR

NR

NR

NR

1

NR

NR

5

NR

NR

NR

6/52 (12%)

Thyroid disease

NR

NR

NR

NR

NR

5

NR

7

22

NR

NR

NR

34/65 (52%)

Morning stiffness reported

1

NR

6

5

NR

6

1

NR

33

NR

1

14

67/106 (63%)

Age at onset (years)

6

10

7.4 (4–10.5)

4.3 (3–11)

5.2 (3–10)

5 (1.7–12)

7

6 (1–13)

7.4 (3.5–11.3)

6.3 (1.1–16)

3

6.9 (2–15)

6.2 (2.4–12.5)

NR

NR

1.6 (0.1–4.5)

3.3 (0.3–9)

NR

1.2 (0.2–3.5)

3

NR

1.6 (0.2–3)

1.2 (0.1–4.5)

1

0.7 (0.1–4.1)

1.1 (0.2–4.8)

Oligoarticular

0

0

2

2

1

1

0

1

4

1

0

3

15

Polyarticular RF-

1

1

4

6

3

8

1

9

30

27

1

24

115

Polyarticular RF+

0

0

0

0

0

0

0

0

0

0

0

0

0

Systemic

0

0

0

1

0

0

0

1

1

0

0

1

4

Psoriatic

0

0

0

0

0

0

0

0

4

5

0

3

12

Enthesitis-related

0

0

0

0

0

0

0

0

4

0

0

3

7

Undifferentiated

0

0

0

0

0

0

0

0

0

0

0

2

2

Normal testing

0

NR

0

0

0

5

0

NR

12

NR

0

16

33/110 (30%)

ANA

1

NR

1

1

1

2

0

NR

8

0

0

12

26/143 (18%)

RF

0

NR

0

0

NR

0

0

NR

0

0

0

0

0/139 (0%)

ESR

1

NR

6

8

4

2

1

NR

24

8/25

1

6

61/136 (45%)

Total (Percent)

Down syndrome Characteristics

Time to diagnosis (years)
Arthritis Subtype

Laboratory tests

NR

NR

NR

NR

NR

1

1

NR

9

3/29

1

6

21/119 (18%)

NR

NR

NR

NR

NR

1

0

NR

5

NR

0

2

8/90 (9%)

Damage present

NR

NR

4

7

NR

2

1

9

28/30

22

1

9

83/136 (61%)

Damage absent

NR

NR

NR

2

NR

2

0

2

2/30

NR

0

15

23/97 (24%)

NR

NR

0

0

0

0

0

0

3

0

0

0

3/153 (2%)

0

NR

4

2

2

1

0

5

11

NR

0

6

31/121 (26%)

Imaging

Uveitis*
Response to first-line therapy**

Notes: *Uveitis was diagnosed via slit lamp eye exam, and this was not exclusive to time of diagnosis, but over the course of disease; **Response to first line-therapy was defined by change in therapy or addition of therapy in setting of
active arthritis.
Abbreviation: NR, not reported.
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Table 2 Differences Between Down Syndrome-Associated Arthritis and Juvenile Idiopathic Arthritis
Variable

Down Syndrome-Associated Arthritis

Juvenile Idiopathic Arthritis

10/1000

1/1000

Polyarticular

Oligoarticular

Equal

Female

6–7 years and 13–20 years

1–3 years and 9–11 years

30–45%

5–35%

Greater than 40%

Less than 25%

Elevated CRP at diagnosis

Less than 20%

Greater than 60%

Elevated ESR at diagnosis

Less than 45%

Greater than 60%

Uveitis (throughout disease course)

Less than 2%

20–30%

Joints with active arthritis

2.9 (5.6)

0.8 (2.0)

Joints with limited range of motion

3.3 (5.5)

0.8 (2.0)

Clinical Juvenile Arthritis Disease Activity Score 10†

4.4 (4.5)

2.6 (4.5)

Medication intolerance

High

Low

Medication effectiveness

Low

High

Prevalence
Most common presentation
Sex predilection
Age at onset
Normal laboratory tests* at diagnosis
Imaging damage at diagnosis

Significant Outcome Measure Differences After Treatment n (SD)**

Notes: *Normal laboratory tests defined as normal c-reactive protein (CRP), erythrocyte sedimentation rate (ESR), negative antinuclear antibody (ANA), negative
rheumatoid factor (RF), and negative human leukocyte antigen B27 (HLA-B27). **Modified from reference.13 †Clinical Juvenile Arthritis Disease Activity Score 10; composite
disease activity (0–30), sum of the MD-global (completed by provider, 10-point Likert visual analog scale, 0 = clinically inactive disease), Pt-Global (completed by patient or
caregiver, 10-point Likert visual analog scale, 0 = very good) and number of joints with active arthritis from physical exam capped at a maximum of 10, ≤ 1.0 = inactive
disease.

looking at immune system differences between healthy individuals with DS and neurotypical healthy controls. The
results showed that individuals with DS had significantly increased circulating levels of TNF-α, IL-1β, IFN-γ and
neopterin when compared to neurotypical healthy controls. There were no differences seen in IL-4, IL-6, IL-8 and IL10.36 It has been proposed that the additional interferon receptors encoded on chromosome 21 have created a gene dosage
affect that has increased IFN pathway signaling that contributes to the elevated IFN expression in individuals with DS
and likely contributes to chronic immune dysregulation that leads to an increased incidence of autoimmune and
autoinflammatory diseases in individuals with DS.37–39 Based on these studies DS could be considered an interferonopathy. A study that compared the adaptive immune system of individuals with DA and JIA found noticeable differences
between the two groups. There was expansion of IgM-only memory B cells in DA compared to JIA and decreased
frequency of transitional B cells that may contribute to the immune dysregulation. Individuals with DA were also noted
to have increased TNF and INF-γ responses by CD8− T cells and increased TNF and IL-17A responses by CD8+ T cells
compared to individuals with JIA. There was also significant expansion of Th1/Th17 cells while Treg cells were reduced
in DA. It was also noted that the increased proinflammatory cytokine response was associated with increased T cell
plasticity. There were also cytokine differences noted in inflamed tissue between individuals with DA and JIA with
increased synovial tissue inflammation that showed increased infiltration of T and B cells in those with DA compared to
those with JIA.40 These findings suggest clear differences between those with DA and JIA and may indicate that DA and
JIA are different diseases, however, it may also indicate that the differences in disease presentation between DA and JIA
are a result of the immune dysregulation in those with DS. More studies are needed to determine biologic differences
between DA and JIA and the extent that the immune dysregulation is involved in DA. This area of research could also
identify novel biomarkers that could be used to aid with diagnosis and guide disease monitoring.
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Evaluation of Down Syndrome-Associated Arthritis
Many challenges have been identified that contribute to a delayed or missed diagnosis of DA. One of those challenges is
awareness about of the increased risk of inflammatory arthritis in individuals with DS among families and healthcare
professionals. This has been proposed as part of the reason there is a delay in diagnosis of DA after long-standing
inflammatory musculoskeletal symptoms occur.8–11 Additionally, when families and care providers of children with DS
were surveyed 86% were unaware of their child’s increased risk to develop inflammatory arthritis.14 Others have also
shown that families often are unaware that their child is displaying signs of arthritis,8 and many present to care several
times with inflammatory arthritis symptoms prior to a diagnosis of DA.41 Even after diagnosis of DA, families report
emotional, physical and financial challenges of being a parent and caregiver to an individual with intellectual disability
and additional complex chronic disease42 that affects mobility and requires immunosuppressive therapy in the setting of
increased risk of infection. Other challenges to diagnosis of DA include musculoskeletal findings specific to individuals
with DS such as hypotonia, ligament laxity and delayed motor skills that may mask signs of inflammatory arthritis.
Additionally, poor language skills or autism present in individuals with DS may prevent articulation of joint symptoms.
In a national survey of DS clinic providers, 77% responded that they were aware of the risk for inflammatory arthritis in
DS, however, less than half educated families about the risk, which is likely due to the lack of guidance around screening
and evaluation for DA.43
There are currently no disease specific formal screening tools for DA, but the American Academy of Pediatrics
(AAP) has published a clinical report for the health supervision of children with DS.15 The report discusses ageappropriate guidance on when to screen for specific conditions, when to refer to specialty care for evaluation, and
anticipatory guidance for families as their child with DS ages, however, there is no discussion of increased risk for
arthritis, formal guidance on screening or surveillance of DA. There have been two studies of novel musculoskeletal
screening tools that have been developed and implemented for DA that have both successfully identified individuals
with DA. One study was a tiered musculoskeletal screening clinic that children with DS attended where individuals
with DS were screened with history and musculoskeletal exam, and then those with concern for inflammatory arthritis
were referred for further evaluation by a pediatric rheumatologist to confirm the diagnosis of DA.8 Another study
used a brief musculoskeletal screening questionnaire given to all families and patients seen in the DS clinic. All
individuals with a positive screen had an ESR obtained, and had a musculoskeletal evaluation by a pediatric
rheumatologist with additional laboratory and imaging tests performed if appropriate.14 Despite these two studies,
there are currently no universally accepted DA screening tools that have been used more broadly. In a national survey
of DS clinic providers and pediatric rheumatologists, most responded that they employ a combination of history,
physical exam, laboratory tests, and imaging modalities to screen for DA,18,43 however, there were discrepancies in
preferred laboratory tests and imaging modalities between the DS clinic providers and the pediatrics rheumatologists,
and ultimately, there was no general consensus identified.
JIA is one of the most common causes of uveitis in childhood. It is predominantly anterior, nongranulomatous
inflammation that affects the iris and ciliary body and has insidious onset. Due to this there are universal recommendations
for screening for inflammatory eye disease.44 The lack of inflammatory eye disease noted in DA would suggest a low risk to
develop uveitis. Further, most cases of uveitis seen in DA have a positive HLA-B27 and developed acute uveitis, while none
of the individuals with a positive ANA developed uveitis. This may indicate less need for routine eye screening compared to
those with JIA. An annual slit-lamp eye exam to evaluate for anterior uveitis is probably sufficient for those with DA unless
specific eye issues are identified as about 60% of individuals with DS will have eye abnormalities that are more commonly
seen in individuals with DS, and most of these are identified in the first year of life.15

Diagnostic Criteria of DA
There are currently no diagnostic criteria for DA, and it is generally agreed upon that DA is a diagnosis of inflammatory
arthritis in an individual with DS. This has been challenged as most of the rheumatology community feels that DA is the
same disease as JIA18 as there are many similarities between JIA and DA. Despite this, JIA is idiopathic in nature, and
for it to occur in an individual with DS may contradict that idea. Additionally, there is emerging evidence that there are

58

Powered by TCPDF (www.tcpdf.org)

https://doi.org/10.2147/PHMT.S282646

DovePress

Pediatric Health, Medicine and Therapeutics 2022:13

Dovepress

Jones et al

biologic differences between those with DA and JIA, which is likely caused by immune system dysregulation. Due to this
we would propose DA as a separate disease entity when compared to JIA. The ILAR criteria used to define JIA has been
used by default to classify DA as there are clinical similarities between these two diseases, and DA could be reclassified
as another ILAR subtype of arthritis, as there is overlap between DA and several JIA subtypes. Work is needed to
develop a disease specific diagnostic criterion for DA, which could be adapted from other types of inflammatory arthritis
such as JIA or completely independent. This would increase disease awareness, education, and aid in development of
surveillance and outcome measures for those with DA.

Treatment and Outcomes
Optimal treatment has proven complex as there is no current guidance on ideal therapy or approach to the treatment of
DA. Because of the similarities between DA and JIA, therapies for JIA such as nonsteroidal anti-inflammatory drugs
(NSAIDs), steroids (oral and intraarticular), disease modifying anti-rheumatic drugs (DMARDs) and biologic therapies
have been utilized to treat DA. Many studies have shown that individuals with DA have more aggressive disease that
requires second-line therapy such as DMARDs (Table 1).7,9–11,13,19,21–24 Of the second-line therapies, methotrexate is the
most used DMARD therapy,9,13,18 but leflunomide, sulfasalazine, azathioprine, and hydroxychloroquine have also been
employed to treat DA. In a survey of pediatric rheumatologists, methotrexate was mostly given via subcutaneous route at
a dose of 15mg/m2 once weekly compared to oral formulation and dosages less than 15 mg/m2.18 Of those that report
methotrexate use for individuals with DA, over half of all individuals had it discontinued due to intolerance.9,13 It is well
documented that individuals with DS have intolerance to high dose methotrexate for treatment of leukemia, but also to
low dose methotrexate for treatment of arthritis.9,45,46 Biologic therapies have reportedly been used in many (55% to
75%) individuals with DA, with TNF-inhibitors being the most common biologic agent used.9,13,18 Other biologic
therapies used include: abatacept, tocilizumab, infliximab, anakinra and canakinumab.9,13 Of those with DA who were
treated with biologic therapies, 40% to 60% had at least one change in biologic therapy due to ineffectiveness of the
therapy.9,13 Additionally, when compared to those with JIA, those with DA had significantly more DMARD adverse
events (93% versus 25%), and biologic therapy ineffectiveness (60% versus 17%).13 Steroids have been used as part of
therapy too, but are the most avoided therapy due to the side effect profile related to weight gain, obesity, and comorbid
issues related to DS.18,47
There are currently no validated arthritis disease measures for DA, and those developed and validated for JIA have
been used as surrogates for disease activity with the caveat that measures for JIA were developed specifically for
neurotypical individuals and may not be fully applicable to those with DA. The outcome measures commonly used for
JIA include joints with active arthritis and limited range-of-motion (ROM), physician global assessment of disease
activity (MD-global; 10-point Likert scale, 0 = clinically inactive disease), patient/parent assessment of overall wellbeing (Pt-global; 10-point Likert scale, 0 = very good), and Childhood Health Assessment Questionnaire (CHAQ), which
is a disease-specific measure of functional status developed for JIA and used in clinical practice.48 A clinical Juvenile
Arthritis Disease Activity Score (cJADAS)49 is a composite disease activity score for JIA, and is the sum of the MDglobal, Pt-global and number of joints with active arthritis capped at a maximum score of 10 (cJADAS10). The
cJADAS10 has cutoff values for defining states of disease activity. For oligoarticular disease, inactive disease is defined
as cJADAS10 ≤ 1.0, low disease activity is >1.0 to ≤1.5, moderate disease activity is 1.51 to 4, and high disease activity
is > 4. For polyarticular disease, inactive disease is defined as cJADAS10 ≤ 1.0, low disease activity is >1.0 to ≤ 2.5,
moderate disease activity is 2.51 to 8.5, and > 8.5 is high disease activity.50 Cutoff values have not been established for
other JIA subtypes.
When individuals with DA are evaluated, many have a substantial number of joints with active arthritis and limited
ROM that mostly involves small and medium joints, with high disease activity and elevated MD-global, Pt-global, and
CHAQ scores.9 In a study of individuals with DA that were matched to those with JIA, it was found that those with DA
had less disease burden at diagnosis, were identified sooner compared to those with JIA and were treated aggressively
with early imitation of DMARD and biologic therapy that was not significantly different from those with JIA.
Additionally, there were no significant differences between those with JIA and DA for MD-global, joints with active
arthritis, or JADAS10, but worse Pt-global and CHAQ scores for those with DA compared to those with JIA. At the end
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of the study there were noted improvements in all outcome measures, however, when compared to those with JIA, there
were significantly worse outcomes for all domains (Pt-global, joints with active arthritis and limited ROM, CHAQ,
cJADAS10) except for MD-global, which suggest greater disease burden and worse response to therapy for those with
DA compared to those with JIA.13
For those with systemic-onset JIA (arthritis with fever of at least 2 weeks duration noted to be daily, with quotidian
pattern for at least 3 days, and accompanied by classic rash, lymphadenopathy, hepatosplenomegaly, or serositis) there
has been an increase in parenchymal inflammatory lung disease that appears to be associated with elevated serum level of
IL-18, IFN-γ activation and activated T cell function.51 Of interest, there was an increased prevalence of systemic-onset
JIA-related inflammatory lung disease in those with DS and the disease was more aggressive and burdensome for those
with DS compared to those without DS.52 While the cause of this is unclear there is concern for immune dysregulation in
those with DS that leads to worse outcomes.

Future Research
Evidence supporting proper identification and treatment of DA has been increasing in the past decade, however, there are
still gaps in knowledge that exist. With the increased incidence of DA in those with DS, screening tools are needed to
identify individuals earlier so appropriate therapies can be initiated to improve disease progression and outcomes.
Routine musculoskeletal screening with questionnaires, physical exam, laboratory testing and imaging could be implemented as part of the AAP’s clinical report for the health supervision of children with DS15 to give guidance on when to
screen and when to refer to specialty care. Novel biomarkers could be instrumental as part of a screening tool to support
a diagnosis of DA and to monitor progress and response to therapy as diagnosis of DA can be challenging due to the
unique traits seen in individuals with DS such as ligament laxity, hypotonia, intellectual disability, and delayed
developmental milestones. A better approach to therapy is needed as the current therapies used to treat DA are associated
with increased toxicity and ineffectiveness. A therapy approach specific for those with DA is warranted with medications
that are better tolerated and more effective. With IFN hyperactivation and downstream Janus kinase (JAK) signaling
there have been reports of JAK inhibition as a therapeutic option for those with DS and inflammatory arthritis.53,54 To
determine changes in disease status DA-specific outcome measures are needed, like those with JIA and other rheumatic
disease, to evaluate change and therapy effectiveness over time. In recognition of the of the critical health and quality-oflife needs for individuals with DS, the INCLUDE (Investigation of Co-occurring conditions across the Lifespan to
Understand Down Syndrome) project (nih.gov/include-project) was launched in 2018 by the National Institutes of Health
to investigate conditions that affect individuals with DS. Increased focus on DA research will undoubtedly lead to better
screening, categorization of the disease, improved approach to therapy and better outcomes.

Conclusion
DA continues to be a significant cause of disability for children and adolescents with DS. Education is needed to raise
awareness among families with a child or adolescent with DS and healthcare providers. Through education and routine
screening more children with DA will get the appropriate care they need. Better medications and therapy approaches are
needed for those with DA to mitigate adverse drug affects and drug ineffectiveness, which is problematic for those with
DS. With improved awareness, better screening, and early effective therapy, the outcomes for those with DA should
improve as long-term joint damage and disability are prevented.
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